Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus
-
Published:2021-08-26
Issue:1
Volume:12
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Lin Gu-LungORCID, Drysdale Simon B.ORCID, Snape Matthew D., O’Connor DanielORCID, Brown AnthonyORCID, MacIntyre-Cockett George, Mellado-Gomez Esther, de Cesare MariateresaORCID, Bonsall David, Ansari M. Azim, Öner Deniz, Aerssens Jeroen, Butler Christopher, Bont Louis, Openshaw PeterORCID, Martinón-Torres FedericoORCID, Nair HarishORCID, Bowden RoryORCID, Campbell Harry, Cunningham Steve, Bogaert Debby, Beutels Philippe, Wildenbeest Joanne, Clutterbuck Elizabeth, McGinley Joseph, Thwaites Ryan, Wiseman Dexter, Gómez-Carballa Alberto, Rodriguez-Tenreiro Carmen, Rivero-Calle Irene, Dacosta-Urbieta Ana, Heikkinen Terho, Meijer Adam, Fischer Thea Kølsen, van den Berge Maarten, Giaquinto Carlo, Abram Michael, Dormitzer Philip, Stoszek Sonia, Gallichan Scott, Rosen Brian, Molero Eva, Machin Nuria, Spadetto Martina, Golubchik TanyaORCID, Pollard Andrew J.ORCID,
Abstract
AbstractHuman respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children globally, but little is known about within-host RSV diversity. Here, we characterised within-host RSV populations using deep-sequencing data from 319 nasopharyngeal swabs collected during 2017–2020. RSV-B had lower consensus diversity than RSV-A at the population level, while exhibiting greater within-host diversity. Two RSV-B consensus sequences had an amino acid alteration (K68N) in the fusion (F) protein, which has been associated with reduced susceptibility to nirsevimab (MEDI8897), a novel RSV monoclonal antibody under development. In addition, several minor variants were identified in the antigenic sites of the F protein, one of which may confer resistance to palivizumab, the only licensed RSV monoclonal antibody. The differences in within-host virus populations emphasise the importance of monitoring for vaccine efficacy and may help to explain the different prevalences of monoclonal antibody-escape mutants between the two subgroups.
Funder
Innovative Medicines Initiative EC | Horizon 2020 Framework Programme European Federation of Pharmaceutical Industries and Associations NIHR Oxford Biomedical Research Centre NIHR Thames Valley and South Midlands Clinical Research Network British Research Council REspiratory Syncytial virus Consortium in EUrope
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference63 articles.
1. Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946–958 (2017). 2. Varga, S. M. & Braciale, T. J. The adaptive immune response to respiratory syncytial virus. Curr. Top. Microbiol. Immunol. 372, 155–171 (2013). 3. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749–1759 (2005). 4. American Academy of Pediatrics. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134, e620–e638 (2014). 5. Ruckwardt, T. J., Morabito, K. M. & Graham, B. S. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 51, 429–442 (2019).
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|